Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian E Serfling

Showing results (51-60 of 72) with videos related to

Pageof 8
Sort By:
Clinical Nuclear Medicine|March 22, 2023
Interobserver Agreement Rates on C-X-C Motif Chemokine Receptor 4-Directed Molecular Imaging and TherapyPhilipp E Hartrampf, Aleksander Kosmala, Sebastian E Serfling, et al.
American Journal of Nuclear Medicine and Molecular Imaging|November 29, 2023
Diagnostic efficacy of C-X-C motif chemokine receptor 4-directed PET/CT in newly diagnosed head and neck squamous cell carcinoma - a head-to-head comparison with [<sup>18</sup>F]FDGYingjun Zhi, Rudolf A Werner, Andreas Schirbel, et al.
Frontiers in Immunology|April 3, 2026
[<sup>18</sup>F]-FDG-PET/CT detects subclinical optic nerve inflammation in giant cell arteritisMichael Gernert, Marc Schmalzing, Matthias Fröhlich, et al.
Cancers|January 21, 2022
Changing Threshold-Based Segmentation Has No Relevant Impact on Semi-Quantification in the Context of Structured Reporting for PSMA-PET/CTPatrick W Mihatsch, Matthias Beissert, Martin G Pomper, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 5, 2023
SUVPhilipp E Hartrampf, Thomas Hüttmann, Anna Katharina Seitz, et al.
Nuclear Medicine Communications|February 22, 2023
Wnt/β-catenin modulating drugs regulate somatostatin receptor expression and internalization of radiolabelled octreotide in neuroendocrine tumor cellsAlexander Weich, Dorothea Rogoll, Melissa Peschka, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 7, 2024
Prognostic Performance of RECIP 1.0 Based on [<sup>18</sup>F]PSMA-1007 PET in Prostate Cancer Patients Treated with [<sup>177</sup>Lu]Lu-PSMA I&TPhilipp E Hartrampf, Thomas Hüttmann, Anna Katharina Seitz, et al.
Clinical Nuclear Medicine|September 27, 2023
Somatostatin Receptor-Directed PET/CT Can Differentiate Between Different Subtypes of Head and Neck ParagangliomasYingjun Zhi, Elena Gerhard-Hartmann, Philipp E Hartrampf, et al.
Molecular Imaging and Biology|August 1, 2024
Interobserver Agreement Rates on CXCR4-Directed PET/CT in Patients with Marginal Zone LymphomaRudolf A Werner, Yingjun Zhi, Niklas Dreher, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 9, 2023
Chemokine receptor-targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [<sup>18</sup>F]FDGAleksander Kosmala, Johannes Duell, Simone Schneid, et al.
Pageof 8

Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
Clinical Nuclear Medicine|March 22, 2023
Interobserver Agreement Rates on C-X-C Motif Chemokine Receptor 4-Directed Molecular Imaging and TherapyPhilipp E Hartrampf, Aleksander Kosmala, Sebastian E Serfling, et al.
American Journal of Nuclear Medicine and Molecular Imaging|November 29, 2023
Diagnostic efficacy of C-X-C motif chemokine receptor 4-directed PET/CT in newly diagnosed head and neck squamous cell carcinoma - a head-to-head comparison with [<sup>18</sup>F]FDGYingjun Zhi, Rudolf A Werner, Andreas Schirbel, et al.
Frontiers in Immunology|April 3, 2026
[<sup>18</sup>F]-FDG-PET/CT detects subclinical optic nerve inflammation in giant cell arteritisMichael Gernert, Marc Schmalzing, Matthias Fröhlich, et al.
Cancers|January 21, 2022
Changing Threshold-Based Segmentation Has No Relevant Impact on Semi-Quantification in the Context of Structured Reporting for PSMA-PET/CTPatrick W Mihatsch, Matthias Beissert, Martin G Pomper, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 5, 2023
SUVPhilipp E Hartrampf, Thomas Hüttmann, Anna Katharina Seitz, et al.
Nuclear Medicine Communications|February 22, 2023
Wnt/β-catenin modulating drugs regulate somatostatin receptor expression and internalization of radiolabelled octreotide in neuroendocrine tumor cellsAlexander Weich, Dorothea Rogoll, Melissa Peschka, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 7, 2024
Prognostic Performance of RECIP 1.0 Based on [<sup>18</sup>F]PSMA-1007 PET in Prostate Cancer Patients Treated with [<sup>177</sup>Lu]Lu-PSMA I&TPhilipp E Hartrampf, Thomas Hüttmann, Anna Katharina Seitz, et al.
Clinical Nuclear Medicine|September 27, 2023
Somatostatin Receptor-Directed PET/CT Can Differentiate Between Different Subtypes of Head and Neck ParagangliomasYingjun Zhi, Elena Gerhard-Hartmann, Philipp E Hartrampf, et al.
Molecular Imaging and Biology|August 1, 2024
Interobserver Agreement Rates on CXCR4-Directed PET/CT in Patients with Marginal Zone LymphomaRudolf A Werner, Yingjun Zhi, Niklas Dreher, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 9, 2023
Chemokine receptor-targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [<sup>18</sup>F]FDGAleksander Kosmala, Johannes Duell, Simone Schneid, et al.
Pageof 8